{"id":"W3093968467","doi":"10.1158/1557-3265.ovcasymp18-nt-101","title":"Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Population; Ovarian cancer; Clinical endpoint; Progressive disease; Progression-free survival; Carboplatin; Oncology; Refractory (planetary science); Gastroenterology; Phases of clinical research; Surgery; Clinical trial; Cancer; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001776569,0.001536833,0.002004896,0.0002965321,0.0003767128,0.001080883,0.00105412,0.001175522,0.009177753],"category_scores_gemma":[0.0009873948,0.0006790662,0.00143693,0.0002872282,0.0008331609,0.001180484,0.0003856419,0.003096544,0.001666391],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009105339,"about_ca_system_score_gemma":0.001386729,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004973166,"about_ca_topic_score_gemma":0.001821969,"domain_scores_codex":[0.999595,0.0002019555,0.00002811512,0.00007946241,0.00004311024,0.00005233725],"domain_scores_gemma":[0.9991608,0.0001130922,0.0001722622,0.00007820513,0.0000657005,0.0004099567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8299266,0.07145204,0.004363854,0.001270907,0.001353763,0.0002333492,0.0001455207,0.001376062,0.0339545,0.0002235205,0.004175005,0.0515249],"study_design_scores_gemma":[0.6201556,0.367033,0.006954622,0.00004552307,0.0003667573,0.0003279881,0.00003928951,0.001177405,0.001701663,0.0001608294,0.002002548,0.00003468521],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9838752,0.002441827,0.0009008912,0.0006443189,0.0002051704,0.005703177,0.003079695,0.0001946203,0.002955127],"genre_scores_gemma":[0.9796711,0.001407601,0.002458903,0.001424743,0.0001937594,0.005329996,0.004493965,0.00004469811,0.004975267],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009177753,"threshold_uncertainty_score":0.03070259,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3252451303081464,"score_gpt":0.5403688162190448,"score_spread":0.2151236859108984,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}